共 32 条
[1]
Playford EG(2007)Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: Risk factors for acquisition, infection and consequences J. Hosp. Infect. 65 204-211
[2]
Craig JC(2012)Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance Clin. Microbiol. Infect. 18 268-281
[3]
Iredell JR(2000)Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii J. Clin. Microbiol. 38 4086-4095
[4]
Magiorakos A-P(2006)Functional, biophysical, and structural bases for antibacterial activity of tigecycline Antimicrob. Agents. Chemother. 50 2156-2166
[5]
Corbella X(2014)Decreased susceptibility to tigecycline in Acinetobacter baumannii mediated by a mutation in trm encoding SAM-dependent methyltransferase J. Antimicrob. Chemother. 69 72-76
[6]
Olson MW(2012)Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: Monotherapy or combination therapy? Indian. J. Med. Microbiol. 30 448-452
[7]
Chen Q(2013) activity of sulbactam in combination with imipenem, meropenem, panipenem or cefoperazone against clinical isolates of Acinetobacter baumannii Int. J. Antimicrob. Agents. 41 400-401
[8]
Simsek F(2011)Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens Yonsei. Med. J. 52 879-891
[9]
Ji J(2007)An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii Nat. Rev. Microbiol. 5 939-951
[10]
Lee K(2008)Acinetobacter baumannii: emergence of a successful pathogen Clin. Microbiol. Rev. 21 538-582